SPI Generative AI: Tempus Makes Data Valuable With Generative AI

Published 28/02/2024

Lifesciences and pharmaceuticals are heavily dependent on data. However, simply having access to data is not enough. Tempus hopes the inclusion of generative AI will help make the data on offer more usable

The Insight is part of Signify Research's Premium Insight – Generative AI subscription service.

To view the full insight on this development hit the Request Access button above for either a complimentary one month trial or to purchase a subscription. 

The Signify Research's Premium Insight – Generative AI subscription service provides:

  • Approximately 100 actionable and up to the moment Premium Insights per year.
  • A subscription to Signify Premium Insights – Generative AI provides compelling thought leadership on the most pertinent developments in healthcare technology.
  • This service utilises Signify Research’s expansive market data to properly appraise and interpret breaking news stories.
  • Major market moves and industry-changing announcements are evaluated as they unfold, and the considered opinions of Signify Research’s expert analysts are shared to provide insight into current developments.
  • Key vendors, technologies and conferences are followed, with updates carefully scrutinised to ensure that the most important details are revealed and properly assessed.